GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocure Technology Inc (XCNQ:CURE) » Definitions » Cyclically Adjusted Book per Share

Biocure Technology (XCNQ:CURE) Cyclically Adjusted Book per Share : C$0.15 (As of Dec. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Biocure Technology Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Biocure Technology's adjusted book value per share for the three months ended in Dec. 2024 was C$0.128. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is C$0.15 for the trailing ten years ended in Dec. 2024.

During the past 12 months, Biocure Technology's average Cyclically Adjusted Book Growth Rate was -21.10% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -18.80% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -18.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Biocure Technology was -14.60% per year. The lowest was -18.80% per year. And the median was -17.55% per year.

As of today (2025-06-02), Biocure Technology's current stock price is C$0.045. Biocure Technology's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2024 was C$0.15. Biocure Technology's Cyclically Adjusted PB Ratio of today is 0.30.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Biocure Technology was 30.75. The lowest was 0.10. And the median was 3.35.


Biocure Technology Cyclically Adjusted Book per Share Historical Data

The historical data trend for Biocure Technology's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocure Technology Cyclically Adjusted Book per Share Chart

Biocure Technology Annual Data
Trend Mar15 Mar16 Mar17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.34 0.28 0.23 0.19 0.15

Biocure Technology Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.18 0.17 0.16 0.15

Competitive Comparison of Biocure Technology's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Biocure Technology's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocure Technology's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocure Technology's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Biocure Technology's Cyclically Adjusted PB Ratio falls into.


;
;

Biocure Technology Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biocure Technology's adjusted Book Value per Share data for the three months ended in Dec. 2024 was:

Adj_Book= Book Value per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.128/127.3637*127.3637
=0.128

Current CPI (Dec. 2024) = 127.3637.

Biocure Technology Quarterly Data

Book Value per Share CPI Adj_Book
201503 0.425 99.789 0.542
201506 0.421 100.500 0.534
201509 0.417 100.421 0.529
201512 0.409 99.947 0.521
201603 0.408 101.054 0.514
201606 0.405 102.002 0.506
201609 0.396 101.765 0.496
201612 -0.058 101.449 -0.073
201703 0.390 102.634 0.484
201706 0.385 103.029 0.476
201709 0.380 103.345 0.468
201712 0.278 103.345 0.343
201803 0.220 105.004 0.267
201806 0.208 105.557 0.251
201809 0.204 105.636 0.246
201812 0.084 105.399 0.102
201903 0.138 106.979 0.164
201906 0.093 107.690 0.110
201909 0.099 107.611 0.117
201912 -0.027 107.769 -0.032
202003 -0.009 107.927 -0.011
202006 -0.020 108.401 -0.023
202009 -0.068 108.164 -0.080
202012 -0.181 108.559 -0.212
202103 -0.198 110.298 -0.229
202106 -0.297 111.720 -0.339
202109 -0.251 112.905 -0.283
202112 -0.045 113.774 -0.050
202203 -0.064 117.646 -0.069
202206 -0.081 120.806 -0.085
202209 -0.097 120.648 -0.102
202212 -0.163 120.964 -0.172
202303 -0.185 122.702 -0.192
202306 0.298 124.203 0.306
202309 0.285 125.230 0.290
202312 0.153 125.072 0.156
202403 0.151 126.258 0.152
202406 0.149 127.522 0.149
202409 0.148 127.285 0.148
202412 0.128 127.364 0.128

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Biocure Technology  (XCNQ:CURE) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Biocure Technology's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.045/0.15
=0.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Biocure Technology was 30.75. The lowest was 0.10. And the median was 3.35.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Biocure Technology Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Biocure Technology's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocure Technology Business Description

Industry
Traded in Other Exchanges
Address
1055 West Hastings Street, Suite 300, Vancouver, BC, CAN, V6E 2E9
Biocure Technology Inc is a biopharmaceutical company specializing in the development and potential commercialization of biosimilar pharmaceutical products. It is Developing Biosimilars and CAR-T Cell pharmaceuticals. Its products are CAR-T Cell Therapy, Interferon Beta, Ranibizumab, and PEG-Filgrastim.
Executives
Konstantin Lichtenwald Director, Senior Officer

Biocure Technology Headlines